Literature DB >> 24922693

Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies.

Hyun Jung Kim1, Eun Young Choi1, Hyun Jung Jin1, Kyeong-Cheol Shin2.   

Abstract

AIM: We performed this study to evaluate the frequency of epidermal growth factor receptor (EGFR) mutations and their association with the histological subtype of lung adenocarcinoma diagnosed via small biopsy specimens. PATIENTS AND METHODS: Three hundred and fifty-nine lung adenocarcinoma specimens were tested for EGFR mutation by a direct sequencing method. In 135 patients, histological subtypes were classified according to the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. We compared the EGFR mutation frequency by clinicopathological characteristics.
RESULTS: We detected 135 (37.6%) EGFR mutations and the incidence was highest in women who never smoked (54.6%). With regard to histological subtype, the highest prevalence of EGFR mutation was found in papillary (81.3%), followed by lepidic (70.4%), acinar (58.1%) and solid (28.3%) tumor types. In addition, the expression of thyroid transcription factor-1 was significantly higher in tumors with the EGFR mutation than in those without (p<0.001).
CONCLUSION: The histological subtype of adenocarcinoma can be predictive of existing EGFR mutation, although the histology was confirmed using only small biopsies. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  EGFR; Lung adenocarcinoma; epidermal growth factor receptor mutation; small biopsy

Mesh:

Substances:

Year:  2014        PMID: 24922693

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Authors:  Maria A Velez; Timothy F Burns
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma.

Authors:  Rolandas Zablockis; Edvardas Žurauskas; Edvardas Danila; Vygantas Gruslys
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

3.  Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.

Authors:  Sheng-Yi Lin; Hsiu-Hui Chang; Yi-Hua Lai; Ching-Hsiung Lin; Min-Hsuan Chen; Gee-Chen Chang; Meng-Feng Tsai; Jeremy J W Chen
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

4.  Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.

Authors:  Boram Lee; Taebum Lee; Se-Hoon Lee; Yoon La Choi; Joungho Han
Journal:  Oncotarget       Date:  2016-04-26

5.  Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients.

Authors:  Tengteng Wang; Yi Zhang; Baodong Liu; Mu Hu; Naikang Zhou; Xiuyi Zhi
Journal:  Thorac Cancer       Date:  2017-09-20       Impact factor: 3.500

6.  Model for predicting EGFR mutation status in lung cancer.

Authors:  Lam Nguyen Ho; Thuong Vu Le
Journal:  Breathe (Sheff)       Date:  2019-12

7.  Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification.

Authors:  Sara Boukansa; Zineb Benbrahim; Sanaa Gamrani; Sanae Bardai; Laila Bouguenouch; Asmae Mazti; Nadia Boutahiri; Mounia Serraj; Bouchra Amara; Yassine Ouadnouni; Mohamed Smahi; Badreeddine Alami; Nawfel Mellas; Hinde El Fatemi
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

8.  Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.

Authors:  Venkata Nagarjuna Maturu; Navneet Singh; Amanjit Bal; Nalini Gupta; Ashim Das; Digambar Behera
Journal:  Lung India       Date:  2016 May-Jun

9.  Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Guangliang Qiang; Wei Huang; Chaoyang Liang; Rui Xu; Jue Yan; Yanyan Xu; Y E Wang; Jiping DA; Bin Shi; Yongqing Guo; Deruo Liu
Journal:  Oncol Lett       Date:  2016-01-27       Impact factor: 2.967

10.  Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.

Authors:  Won Chul Chang; Han Kyeom Kim; Bong Kyung Shin
Journal:  Oncol Rep       Date:  2019-11-04       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.